{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:51Z","timestamp":1793814051213,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For Human Papillomavirus (HPV) vaccination to be delivered effectively, countries must transition from campaign-based introduction to integration within the routine immunization schedule. While existing literature provides insights into the effectiveness of HPV campaigns and barriers to initial vaccine acceptance, there is a dearth of stakeholder-informed implementation research around the transition from campaign to routine delivery. This study aimed to explore the experiences and perspectives of key stakeholders involved in the HPV vaccine campaign in Nigeria to generate stakeholder-driven recommendations for the effective and sustainable integration of the vaccine into the country\u2019s routine immunization schedule and strengthen national capacity for introducing and sustaining future new vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study adopted a qualitative, exploratory research design. The research was conducted across nine Nigerian states, representing five of the six geopolitical zones. Participants were purposively sampled, encompassing 140 stakeholders (30 Key Informant Interviews, 110 In-depth Interviews). Data were collected using semi-structured interview guides, audio-recorded, transcribed verbatim, and thematically analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Stakeholder recommendations emphasize that effectively integrating the HPV vaccine into routine immunization in Nigeria demands a multi-pronged strategy. This includes comprehensive strategies for awareness, engagement, and mobilization; continuous workforce training and motivation; robust data systems and reporting; effective management of misinformation; and intensification campaign. Additionally, early and thorough planning, fostering government ownership, optimizing operational logistics, ensuring consistent funding, and maintaining vaccine availability are critical. These insights provide valuable, transferable lessons for the introduction and sustained implementation of future vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The transition of the Human Papillomavirus (HPV) vaccine from a campaign-driven approach to routine immunization in Nigeria represents a critical juncture, offering both significant challenges and unparalleled opportunities to strengthen the national health system. Policy priorities should include institutionalizing periodic intensification programs, strengthening community engagement, standardizing immunization data systems, securing sustainable financing, and enhancing primary healthcare infrastructure. By addressing these priorities, Nigeria can achieve equitable HPV vaccine coverage and strengthen its capacity for future vaccine initiatives, ensuring a lasting public health impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-14225-7","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:57:44Z","timestamp":1771390664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From campaign to continuity: stakeholders\u2019 recommendations for integrating HPV vaccination into Nigeria\u2019s healthcare system"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2218-2254","authenticated-orcid":false,"given":"Catherine Nabiem","family":"Akpen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-0078","authenticated-orcid":false,"given":"Edikan","family":"Uwatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahfus","family":"Dauda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stallone","family":"Ngobua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daradara","family":"Kubura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5303-5475","authenticated-orcid":false,"given":"Sidney","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-2561","authenticated-orcid":false,"given":"Sunday","family":"Atobatele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeyinka","family":"Ogunsanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3779-9763","authenticated-orcid":false,"given":"Hilary","family":"Okagbue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"14225_CR1","doi-asserted-by":"crossref","unstructured":"Pandey D, Bansal S, Samdariya D, Mounika A, Sirisha V. Introduction to cervical cancer. In: Epigenetics of cervical cancer. Singapore: Springer Nature Singapore; 2025 Apr 11 (pp. 1 -14).","DOI":"10.1007\/978-981-96-3985-4_1"},{"key":"14225_CR2","doi-asserted-by":"publisher","first-page":"101460","DOI":"10.1016\/j.gore.2024.101460","volume":"54","author":"S Reza","year":"2024","unstructured":"Reza S, Anjum R, Khandoker RZ, Khan SR, Islam MR, Dewan SM. Public health concern-driven insights and response of low-and middle-income nations to the world health organization call for cervical cancer risk eradication. Gynecologic Oncol Rep. 2024;54:101460.","journal-title":"Gynecologic Oncol Rep"},{"issue":"4","key":"14225_CR3","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.gendis.2022.09.014","volume":"10","author":"M Mann","year":"2023","unstructured":"Mann M, Singh VP, Kumar L. Cervical cancer: A Tale from HPV infection to PARP inhibitors. Genes Dis. 2023;10(4):1445\u201356.","journal-title":"Genes Dis"},{"key":"14225_CR4","doi-asserted-by":"publisher","first-page":"552028","DOI":"10.3389\/fpubh.2020.552028","volume":"8","author":"AJ Kombe Kombe","year":"2021","unstructured":"Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, Jin T. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2021;8:552028.","journal-title":"Front Public Health"},{"key":"14225_CR5","doi-asserted-by":"publisher","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","volume":"144","author":"L Bruni","year":"2021","unstructured":"Bruni L, Saura-L\u00e1zaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, Afsar OZ, LaMontagne DS, Mosina L, Contreras M, Velandia-Gonz\u00e1lez M. HPV vaccination introduction worldwide and WHO and UNICEF estimates of National HPV immunization coverage 2010\u20132019. Prev Med. 2021;144:106399.","journal-title":"Prev Med"},{"key":"14225_CR6","doi-asserted-by":"publisher","first-page":"1112981","DOI":"10.3389\/fpubh.2023.1112981","volume":"11","author":"DE Waheed","year":"2023","unstructured":"Waheed DE, Bolio A, Guillaume D, Sidibe A, Morgan C, Karafillakis E, Holloway M, Van Damme P, Limaye R, Vorsters A. Planning, implementation, and sustaining high coverage of human papillomavirus (HPV) vaccination programs: what works in the context of low-resource countries? Front Public Health. 2023;11:1112981.","journal-title":"Front Public Health"},{"key":"14225_CR7","doi-asserted-by":"crossref","unstructured":"Xu MA, Choi J, Capasso A, DiClemente RJ. Improving HPV vaccination uptake among adolescents in low resource settings: sociocultural and socioeconomic barriers and facilitators. Adolesc Health Med Ther. 2024 Dec 31:73\u201382.","DOI":"10.2147\/AHMT.S394119"},{"issue":"1","key":"14225_CR8","doi-asserted-by":"publisher","first-page":"2500264","DOI":"10.1080\/21645515.2025.2500264","volume":"21","author":"S Agha","year":"2025","unstructured":"Agha S, Zeng W. Cost-effectiveness of a behavioral insights-informed digital campaign to increase HPV vaccination in Bangladesh. Hum Vaccines Immunotherapeutics. 2025;21(1):2500264.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"14225_CR9","doi-asserted-by":"crossref","unstructured":"Wu J, Yang R. Campaign governance and playfulness: unraveling Chinese HPV immunization promotion efforts on Douyin. Healthcare. 2024;12(16):1657.","DOI":"10.3390\/healthcare12161657"},{"key":"14225_CR10","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.vaccine.2023.08.057","volume":"42","author":"KS Kouassi","year":"2024","unstructured":"Kouassi KS, Chisupa E, Clarke A, Massenon I, Miano C, Mutuku F, Wanyoike S, Mumba M, Diouf R, Morgan C, Jennings MC. Pandemic-related resilience in HPV vaccination programmes\u2013Perspectives from selected countries in Africa on what it will take to vaccinate 90% of girls by 2030. Vaccine. 2024;42:S33\u20136.","journal-title":"Vaccine"},{"key":"14225_CR11","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.vaccine.2023.09.009","volume":"42","author":"A Bolio","year":"2024","unstructured":"Bolio A, Kyesi F, Miano CW, Tefera YL, Kinteh M, Beygum J, Chisupa E, Koussai KS, Guillaume D, Biey J, Ndiaye C. Routine HPV vaccination: reflection on delivery strategies based on countries\u2019 experiences. Vaccine. 2024;42:S37\u201340.","journal-title":"Vaccine"},{"issue":"11","key":"14225_CR12","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1080\/21645515.2021.1961466","volume":"17","author":"C Cadeddu","year":"2021","unstructured":"Cadeddu C, Castagna C, Sapienza M, Lanza TE, Messina R, Chiavarini M, Ricciardi W, De Waure C. Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review. Hum Vaccines Immunotherapeutics. 2021;17(11):4470\u201386.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"6","key":"14225_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/heapol\/czaa017","volume":"35","author":"E Amponsah-Dacosta","year":"2020","unstructured":"Amponsah-Dacosta E, Kagina BM, Olivier J. Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan africa: a systematic review. Health Policy Plann. 2020;35(6):701\u201317.","journal-title":"Health Policy Plann"},{"issue":"11","key":"14225_CR14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/vaccines12111293","volume":"12","author":"F Branda","year":"2024","unstructured":"Branda F, Pavia G, Ciccozzi A, Quirino A, Marascio N, Gigliotti S, Matera G, Romano C, Locci C, Azzena I, Pascale N. Human papillomavirus (HPV) vaccination: progress, challenges, and future directions in global immunization strategies. Vaccines. 2024;12(11):1293.","journal-title":"Vaccines"},{"key":"14225_CR15","doi-asserted-by":"publisher","first-page":"101734","DOI":"10.1016\/j.pmedr.2022.101734","volume":"26","author":"AM Akumbom","year":"2022","unstructured":"Akumbom AM, Lee JJ, Reynolds NR, Thayer W, Wang J, Slade E. Cost and effectiveness of HPV vaccine delivery strategies: A systematic review. Prev Med Rep. 2022;26:101734.","journal-title":"Prev Med Rep"},{"issue":"12","key":"14225_CR16","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.vaccine.2021.02.006","volume":"39","author":"MS Rane","year":"2021","unstructured":"Rane MS, Page LC, McVeigh E, Miller K, Baure D, Halloran ME, Duchin JS. Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns. Vaccine. 2021;39(12):1765\u201372.","journal-title":"Vaccine"},{"key":"14225_CR17","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Global Strategy. 17 November 2020. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240014107. (accessed on 1 June 2024)."},{"issue":"Suppl 1","key":"14225_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11121-023-01568-4","volume":"25","author":"J Tsui","year":"2024","unstructured":"Tsui J, Shin M, Sloan K, Martinez B, Palinkas LA, Baezconde-Garbanati L, Cantor JC, Hudson SV, Crabtree BF. Understanding clinic and community member experiences with implementation of evidence-based strategies for HPV vaccination in safety-net primary care settings. Prev Sci. 2024;25(Suppl 1):147\u201362.","journal-title":"Prev Sci"},{"issue":"1","key":"14225_CR19","doi-asserted-by":"publisher","first-page":"e0291990","DOI":"10.1371\/journal.pone.0291990","volume":"19","author":"D Guillaume","year":"2024","unstructured":"Guillaume D, Waheed DE, Schleiff M, Muralidharan KK, Vorsters A, Limaye RJ. Global perspectives of determinants influencing HPV vaccine introduction and scale-up in low-and middle-income countries. PLoS ONE. 2024;19(1):e0291990.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"14225_CR20","doi-asserted-by":"publisher","first-page":"A11","DOI":"10.1186\/1748-5908-10-S1-A11","volume":"10","author":"LR Smith","year":"2015","unstructured":"Smith LR, Damschroder L, Lewis CC, Weiner B. The consolidated framework for implementation research: advancing implementation science through real-world applications, adaptations, and measurement. Implement Science: IS. 2015;10(Suppl 1):A11. https:\/\/doi.org\/10.1186\/1748-5908-10-S1-A11.","journal-title":"Implement Science: IS"},{"key":"14225_CR21","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. ResearchGate. 2006. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"ResearchGate"},{"issue":"4","key":"14225_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1108\/QRJ-08-2022-0116","volume":"23","author":"OC Enworo","year":"2023","unstructured":"Enworo OC. Application of Guba and lincoln\u2019s parallel criteria to assess trustworthiness of qualitative research on Indigenous social protection systems. Qualitative Res J. 2023;23(4):372\u201384.","journal-title":"Qualitative Res J"},{"issue":"2","key":"14225_CR23","doi-asserted-by":"publisher","first-page":"e0263381","DOI":"10.1371\/journal.pone.0263381","volume":"17","author":"K Singh","year":"2022","unstructured":"Singh K, Lima G, Cha M, Cha C, Kulshrestha J, Ahn Y-Y, Varol O. Misinformation, believability, and vaccine acceptance over 40 countries: takeaways from the initial phase of the COVID-19 infodemic. PLoS ONE. 2022;17(2):e0263381.","journal-title":"PLoS ONE"},{"key":"14225_CR24","doi-asserted-by":"publisher","first-page":"115152","DOI":"10.1016\/j.socscimed.2022.115152","volume":"307","author":"S Vanderslott","year":"2022","unstructured":"Vanderslott S, Enria L, Bowmer A, Kamara A, Lees S. Attributing public ignorance in vaccination narratives. Soc Sci Med. 2022;307:115152.","journal-title":"Soc Sci Med"},{"issue":"8","key":"14225_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2471\/BLT.11.097253","volume":"90","author":"A Binagwaho","year":"2012","unstructured":"Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in rwanda\u2019s National human papillomavirus vaccination programme. Bull World Health Organ. 2012;90(8):623\u20138. https:\/\/doi.org\/10.2471\/BLT.11.097253.","journal-title":"Bull World Health Organ"},{"key":"14225_CR26","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1016\/j.vaccine.2021.08.042","volume":"40","author":"RM Casey","year":"2022","unstructured":"Casey RM, Adrien N, Badiane O, Diallo A, Loko Roka J, Brennan T, Doshi R, Garon J, Loharikar A. National introduction of HPV vaccination in Senegal\u2014Successes, challenges, and lessons learned. Vaccine. 2022;40:A10\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.042.","journal-title":"Vaccine"},{"issue":"4","key":"14225_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/tbm\/ibae010","volume":"14","author":"G Maynard","year":"2024","unstructured":"Maynard G, Akpan IN, Meadows RJ, Fulda KG, Patel DA, Leidner V, Taskin T, Gehr AW, Lu Y, Matches S, Thompson EL. Evaluation of a human papillomavirus vaccination training implementation in clinical and community settings across different clinical roles. Translational Behav Med. 2024;14(4):249\u201356.","journal-title":"Translational Behav Med"},{"issue":"Suppl 2","key":"14225_CR28","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.vaccine.2024.04.090","volume":"42","author":"R Njogu","year":"2024","unstructured":"Njogu R, Deb Roy A, Bagudu Z, Borda H, Jurgensmeyer M, Muralidharan K, Limaye R. Effective communication by health care workers to promote HPV vaccination: lessons learned from Kenya, India, and Nigeria. Vaccine. 2024;42(Suppl 2):S27\u201332.","journal-title":"Vaccine"},{"key":"14225_CR29","doi-asserted-by":"crossref","unstructured":"Osaghae I, Darkoh C, Chido-Amajuoyi OG, Chan W, Padgett Wermuth P, Pande M, Cunningham SA, Shete S. HPV vaccination training of healthcare providers and perceived self-efficacy in HPV vaccine-hesitancy counseling. Vaccines. 2022;10(12):2025.","DOI":"10.3390\/vaccines10122025"},{"key":"14225_CR30","doi-asserted-by":"crossref","unstructured":"Lawrence MR, Fuller BP, Isabirye HK, Kyozira C, Makumbi I, Bakainaga A, Moore CC, Ssekitoleko R. Health data reporting challenges in the age of DHIS2: a mixed-methods review in the Teso sub-region of Uganda. medRxiv [Preprint]. 2024:2024.09.18.24313921","DOI":"10.1101\/2024.09.18.24313921"},{"issue":"3","key":"14225_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1071\/SH09137","volume":"7","author":"JML Brotherton","year":"2010","unstructured":"Brotherton JML, Kaldor JM, Garland SM. Monitoring the control of human papillomavirus (HPV) infection and related diseases in australia: towards a National HPV surveillance strategy. Sex Health. 2010;7(3):310\u20139. https:\/\/doi.org\/10.1071\/SH09137.","journal-title":"Sex Health"},{"key":"14225_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1186\/s12889-022-13975-3","volume":"22","author":"M Egbon","year":"2022","unstructured":"Egbon M, Ojo T, Aliyu A, Bagudu ZS. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community. BMC Public Health. 2022;22:1611.","journal-title":"BMC Public Health"},{"key":"14225_CR33","first-page":"100549","volume":"20","author":"G Murewanhema","year":"2024","unstructured":"Murewanhema G, Moyo E, Dzobo M, Mandishora-Dube RS, Dzinamarira T. Human papilloma virus vaccination in the resource-limited settings of sub-Saharan africa: challenges and recommendations. Vaccine: X. 2024;20:100549.","journal-title":"Vaccine: X"},{"issue":"1","key":"14225_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12879-024-09222-2","volume":"24","author":"MC Simuyemba","year":"2024","unstructured":"Simuyemba MC, Chama-Chiliba CM, Chompolola A, Sinyangwe A, Bchir A, Asiimwe G, Chibwesha C, Masiye F. An evaluation of the cost of human papilloma virus (HPV) vaccine delivery in Zambia. BMC Infect Dis. 2024;24(1):369.","journal-title":"BMC Infect Dis"},{"key":"14225_CR35","doi-asserted-by":"publisher","first-page":"100496","DOI":"10.1016\/j.oor.2024.100496","volume":"10","author":"AS Dhane","year":"2024","unstructured":"Dhane AS. Empowering lmics: HPV vaccination programs as a shield against HPV-related oral cancers. Oral Oncol Rep. 2024;10:100496.","journal-title":"Oral Oncol Rep"},{"key":"14225_CR36","doi-asserted-by":"crossref","unstructured":"Wu D, Liu P, Song D, Wang H, Chen S, Tang W, Zhao X, Zhao F, Wang Y. Implementing the free HPV vaccination for eligible girls in Shenzhen, Guangdong Province of China: experience, challenges, and lessons. 2023.","DOI":"10.21203\/rs.3.rs-2881863\/v1"},{"issue":"1","key":"14225_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40249-023-01136-6","volume":"12","author":"X-L Zhao","year":"2023","unstructured":"Zhao X-L, Hu S-Y, Hu J-W, Wang H-H, Wen T-M, Feng Y-S, Qiao Y-L, Zhao F-H, Zhang Y. Tackling barriers to scale up human papillomavirus vaccination in china: progress and the way forward. Infect Dis Poverty. 2023;12(1):86. https:\/\/doi.org\/10.1186\/s40249-023-01136-6.","journal-title":"Infect Dis Poverty"},{"issue":"21","key":"14225_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijerph20216998","volume":"20","author":"E Asempah","year":"2023","unstructured":"Asempah E, Wiktorowicz ME. Understanding HPV vaccination policymaking in rwanda: A case of health prioritization and Public-Private-Partnership in a Low-Resource setting. Int J Environ Res Public Health. 2023;20(21):21. https:\/\/doi.org\/10.3390\/ijerph20216998.","journal-title":"Int J Environ Res Public Health"},{"key":"14225_CR39","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/S2214-109X(18)30176-1","volume":"6","author":"J Bao","year":"2018","unstructured":"Bao J, McAlister H, Robson J, Wang A, Koswin K, Sayinzoga F, Sibomana H, Uwizihiwe J, de Dieu Hakizimana J, Nyamusore J, Kabeja A, Wong J, Zlotkin S. Near universal childhood vaccination rates in rwanda: how was this achieved and can it be duplicated? Lancet Global Health. 2018;6:S47. https:\/\/doi.org\/10.1016\/S2214-109X(18)30176-1.","journal-title":"Lancet Global Health"},{"key":"14225_CR40","unstructured":"CHIC Project. (2024). Post-symposium engagement on HPV vaccination progress 2024. CHIC. https:\/\/stophpv.org\/postsymp_2024report\/."},{"issue":"3","key":"14225_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/wmh3.428","volume":"13","author":"N Myers","year":"2021","unstructured":"Myers N. Information sharing and community resilience: toward a whole community approach to surveillance and combatting the infodemic. World Med Health Policy. 2021;13(3):581\u201392.","journal-title":"World Med Health Policy"},{"issue":"2","key":"14225_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14760584.2019.1574224","volume":"18","author":"A Guignard","year":"2019","unstructured":"Guignard A, Praet N, Jusot V, Bakker M, Baril L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019;18(2):119\u201331.","journal-title":"Expert Rev Vaccines"},{"key":"14225_CR43","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.vaccine.2022.11.038","volume":"42","author":"F Olayinka","year":"2024","unstructured":"Olayinka F, Sauer M, Menning L, Summers D, Wonodi C, Mackay S, MacDonald NE, Figueroa JP, Andriamitantsoa B, Bonsu G, Haldar P. Building and sustaining public and political commitment to the value of vaccination: recommendations for the immunization agenda 2030 (Strategic priority area 2). Vaccine. 2024;42:S43\u201353.","journal-title":"Vaccine"},{"key":"14225_CR44","doi-asserted-by":"crossref","unstructured":"Omoleke SA, Bayugo YV, Oyene UE, Abrahams J, Gobat N, Good S, Manandhar M, Elfeky S, Hernandez Bonilla AG, Valentine N, Alger J. WHO community engagement package: a reinforcement of an inclusive approach to global public health. Int J Epidemiol Health Sci. 2021;2.","DOI":"10.51757\/IJEHS.2.7.2021.244835"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14225-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:24:06Z","timestamp":1781634246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14225"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14225-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the National Health Research Ethics Committee (NHREC) with approval number NHREC\/01\/01\/2007-31\/10\/2024. Verbal informed consent was obtained from all participants after explaining the study\u2019s purpose, procedures, potential risks, and benefits. Anonymity and confidentiality were strictly maintained using coded identifiers. No personally identifying information was recorded. All data were stored electronically in password-protected systems accessible only to authorized research personnel. The study adhered to the ethical principles of the Declaration of Helsinki (2018 as revised).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"394"}}